Navigation Links
Pharmaceutical advances offer new options for health outcomes
Date:5/20/2013

Orlando, FL (May 20, 2013) Research presented at Digestive Disease Week (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C.

An international study holds promising results for patients suffering from IBS-D. In the phase II study, researchers found that the drug ibodutant significantly improved symptoms in more than 50 percent of the individuals treated.

"While there's been a lot of progress in medicines for IBS with constipation, we haven't seen the same in IBS with diarrhea," said Jan Tack, MD, professor and director of the division of gastroenterology and internal medicine at Leuven University in Belgium. "Up to this point, we haven't been able to provide a pharmaceutical option for this patient group that successfully manages the pain associated with the condition."

IBS is an extremely common condition, affecting an estimated 10 percent of adults. Funded by Menarini, the double-blind, multinational study recruited 559 patients with IBS-D who were randomized and treated with 1, 3 or 10 mg of ibodutant or a placebo. Patients took an oral tablet once daily for eight consecutive weeks. Researchers found that 10 mg was the most effective dose and that it worked best for females.

"These are exciting findings that could bring a lot of relief to many patients," said Dr. Tack said. "We're looking forward to moving into phase III to confirm our findings with a much larger sample of patients."

New therapy for patients with hepatitis C examined

New research suggests that an investigational therapy for patients with hepatitis C can achieve high response rates in a wide range of patients, even those who respond poorly to current treatments. The study examined the safety and efficacy of interferon-free regimens, including three direct-acting antiviral drugs with and without ribavirin, for 12 or 24 weeks, in patients with chronic hepatitis C who were either treatment-nave or had previously failed standard treatment with peginterferon and ribavirin.

In the phase II study, researchers found that the treatment regimens achieved high sustained virologic response (SVR) rates, an efficacy measure of a hepatitis C treatment, in non-cirrhotic patients with HCV genotype-1 (GT 1). SVR was achieved by 98.7 percent of treatment-nave patients and 93.3 percent of prior nonresponders after 12 weeks of treatment with three direct-acting agents with ribavirin.

"Hepatitis C genotype 1 is the most common type of hepatitis in the U.S., and many of these patients are still quite difficult to treat with current interferon-based therapies," said Frederick Nunes, MD, clinical associate professor of medicine at Penn Medicine. "This includes specific populations such as African Americans and patients with high body mass or pre-diabetes. These results suggest that highly effective regimens like this one may overcome that difficulty, without the need for interferon."


'/>"/>

Contact: Aimee Frank
newsroom@gastro.org
407-685-4030
Digestive Disease Week
Source:Eurekalert

Related medicine news :

1. Active Pharmaceutical Ingredients (API) Market in Europe Will Reach $38,255.67 Million By 2017- Pricing and Reimbursement Initiatives Supporting Generic Drug Growth
2. Cloud Computing in Pharmaceutical Research and Development - Virtualization of Data through the Cloud Optimizes Next-Generation DNA Sequencing and Clinical Trials Data
3. Aeolus Pharmaceuticals To Present At Taglich Brothers 10th Annual Small Cap Equity Conference
4. TraceLink Leads Pharmaceutical Track and Trace, Big Data and Cloud-based Supply Networks Discussion at LogiPharma Europe Conference
5. Corporate Whistle Blower Center Now Urges Pharmaceutical Insiders Or Physicians To Become A Whistleblower If They Can Prove A Drug Maker Was Knowingly Involved In Bribery
6. Pharmaceutical advertising down but not out
7. Pharmaceutical companies: An $84 million marketing effort in the District of Columbia
8. Survey shows medical students have frequent interactions with pharmaceutical companies
9. Radiopharmaceuticals Market - New Industry Research Report Published by Transparency Market Research
10. Sewage lagoons remove most -- but not all -- pharmaceuticals
11. Pharmaceutical Manufacturing in China Industry Research Report – Now Available from IBISWorld
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join ... This festival offers entertainment for everyone — from the avid gardener to the landscape ... very high quality event held in a grand venue, and we are certainly looking ...
(Date:4/21/2017)... ... April 21, 2017 , ... A new medical study ... replacement patients; post-operative recovery just might be even better than they imagined. Researchers ... osteoarthritis following surgery: 262 patients under 65 and 103 patients over 75. The ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted in 2010 ... bug infestations over the 5-year period. In 2015 10% or US$750 million per annum ... bug infested properties. , The health and economic consequences of bed bug ...
(Date:4/21/2017)... ... April 21, 2017 , ... In a recently released ... a summer camp for kids in Dana Point, parents are challenged to find ways ... writers caution parents to find age appropriate activities that both reinforce their child’s learning ...
(Date:4/20/2017)... Carolina (PRWEB) , ... April 20, 2017 , ... ... of the fourth book in its growing library. The Greener The Grass, ... Quarterback and alumnus of Walnut Grove High School, shares a deeply personal, hard-earned ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... , April 19, 2017 Global Prostate ... report on the prostate cancer therapeutics market analyzes ... market. Increasing prevalence of prostate cancer, launch of ... the development of new drugs & therapeutic biological ... drug due to lesser side effects are some ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: